News Releases

Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS, a rare primary immunodeficiency LEIDEN, Netherlands , Nov. 23, 2022 /PRNewswire/ -- Pharming Group N.V.

Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands , Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for

Pharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022. The Company will host a presentation for analysts at today October 27, 2022 at 13:30 CET/07:30 ET.

Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency   This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days LEIDEN,

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands , Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V.

LEIDEN, The Netherlands , Sept. 7, 2022 /PRNewswire/ -- Pharming Group N.V. (" Pharming ") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries , will present at the H.C. Wainwright 24 th Annual Global Investment Conference , a hybrid meeting based in

Pharming Group N.V. presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022. The Company held an analyst conference call on August 4, 2022 at 13.30 CET/07.30 EST.  To launch the audio webcast recording of the call please click on  this link . 

Implemented by the Centers for Disease Control and Prevention , the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands , Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam:

EMA  accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands , Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will announce financial results for the six months ended 30 June 2022 on Thursday, August 4, 2022. The Company will host a presentation for analysts at 13:30 CET/07:30 EST on August 4, 2022.